A 31-year-old woman comes to the physician because of intermittent episodes of stabbing right lower jaw pain for 6 weeks. The pain is severe, sharp, and lasts for a few seconds. These episodes commonly occur when she washes her face, brushes her teeth, or eats a meal. She does not have visual disturbances, weakness of her facial muscles, or hearing loss. Five weeks ago, she had an episode of acute bacterial sinusitis, which was treated with antibiotics. Which of the following is the most appropriate initial treatment for this patient's condition?
Q272
A 25-year-old woman presents to an urgent care center following a bee sting while at a picnic with her friends. She immediately developed a skin rash and swelling over her arm and face. She endorses diffuse itching over her torso. Past medical history is significant for a mild allergy to pet dander and ragweed. She occasionally takes oral contraceptive pills and diphenhydramine for her allergies. Family history is noncontributory. Her blood pressure is 119/81 mm Hg, heart rate is 101/min, respiratory rate is 21/min, and temperature is 37°C (98.6°F). On physical examination, the patient has severe edema over her face and severe stridor with inspiration at the base of both lungs. Of the following options, this patient is likely experiencing which of the following hypersensitivity reactions?
Q273
A 23-year-old man comes to the emergency department because of a 2-day history of painful swelling of the right hand. There is no associated recent trauma. Physical examination shows a 3 × 3-cm area of induration that is fluctuant and warm to the touch, consistent with an abscess. The patient consents to incision and drainage of the abscess in the emergency department. Following evaluation of the patient's allergy status, a short-acting, local anesthetic drug is administered via subcutaneous infiltration. Which of the following local anesthetics would provide the shortest duration of analgesia?
Q274
A 49-year-old woman is brought to the emergency department for a severe, sudden-onset generalized headache that began while she was riding an exercise bike at home that morning. After quickly getting off the bike and lying down, she lost consciousness. She was unconscious for a period of one minute. When she regained consciousness, she had neck stiffness, nausea, and two episodes of vomiting. She has hypertension. She does not smoke or drink alcohol. Her current medications include chlorthalidone and a multivitamin. She is in severe distress. Her temperature is 37.3°C (99.1F°), pulse is 88/min, respirations are 18/min, and blood pressure is 169/102 mm Hg. A CT scan of the head without contrast shows hyperdense material between the arachnoid mater and the pia mater. The patient is taken to the operating room for surgical clipping and transferred to the intensive care unit. Five days later, she has new-onset focal weakness of her left lower extremity. Her temperature is 37.1°C (98.8°F), pulse is 70/min, respirations are 17/min, and blood pressure is 148/90 mm Hg. Strength is 3/5 in the left lower extremity and 5/5 in the right lower extremity. Which of the following would most likely have been able to prevent this patient's condition?
Q275
A 72-year-old woman comes to the emergency department because of severe pain in her right lower leg for 3 hours. She has also had worsening tingling that started 3 hours before. She has never had such pain in her leg in the past. Over the last couple months, she has occasionally had episodes of palpitations. She has hypertension and type 2 diabetes mellitus. Current medications include hydrochlorothiazide and lisinopril. Her pulse is 88/min and her blood pressure is 135/80 mm Hg. Physical examination shows a cool and pale right leg with delayed capillary filling. Muscle strength and tone in the right calf and foot are reduced. Femoral pulse is present bilaterally. Pedal pulses are absent on the right. Inhibition of which of the following would have most likely prevented this patient's condition?
Q276
A 27-year-old homeless man presents to the emergency department with abdominal pain and vomiting. He has a known history of intravenous drug use and has been admitted to the hospital several times before. On physical examination his temperature is 99°F (37.2°C), blood pressure is 130/85 mmHg, pulse is 90/min, respirations are 19/min, and pulse oximetry is 99% on room air. The patient is in obvious discomfort. There is increased salivation and lacrimation. Pupils are reactive to light and 5 mm bilaterally. Cardiopulmonary exam is unremarkable. There is diffuse abdominal tenderness to palpation with no rebound or guarding. Which of the following interventions would have prevented this patient’s current condition?
Q277
A 45-year-old man with a history of recurrent gouty arthritis comes to the physician for a follow-up examination. Four weeks ago, he was diagnosed with hyperuricemia and treatment with allopurinol was begun. Since then, he has had another acute gout attack, which resolved after treatment with ibuprofen. His temperature is 37.1°C (98.8°F). Physical examination shows painless, chalky nodules on the metatarsophalangeal joint of his right foot. Laboratory studies show:
Serum
Creatinine 1.0 mg/dL
Uric acid 8.5 mg/dL
Cholesterol 278 mg/dL
Urine
Uric acid 245 mg/24 h (N = 240-755)
From a pharmacological mechanism perspective, based on the urine findings, this patient would theoretically benefit from treatment with which of the following drugs to prevent future gout attacks?
Q278
A group of investigators is studying a drug to treat refractory angina pectoris. This drug works by selectively inhibiting the late influx of sodium ions into cardiac myocytes. At high doses, the drug also partially inhibits the degradation of fatty acids. Which of the following is the most likely effect of this drug?
Q279
A 35-year-old woman comes to the physician because of recurring episodes of headache for the past 5 months. During this period, she has had headaches for approximately 20 days per month. The episodes last for about 2 hours each. She describes the headaches as dull, pressing, and non-pulsating holocranial pain. The symptoms do not increase with exertion. She has no vomiting, nausea, phonophobia, or photophobia. She has two children and has had a great deal of stress lately due to frequent fights with her husband. She appears well. Vital signs are within normal limits. Physical examination shows no abnormalities. Which of the following is the most appropriate pharmacotherapy for this patient?
Q280
A 47-year-old female presents to her primary care physician complaining of diarrhea and fatigue. She reports an eight-month history of increasingly frequent diarrhea, fatigue, and muscle weakness. She currently has over 15 episodes of watery diarrhea per day despite fasting. Her past medical history is notable for diabetes that is well controlled with metformin. Her temperature is 98.6°F (37°C), blood pressure is 100/70 mmHg, pulse is 95/min, and respirations are 18/min. Physical examination is notable for mild diffuse abdominal pain and facial flushing. An upper endoscopy is performed and the stomach is found to be less acidic than normal. In addition to correcting this patient’s dehydration, which of the following medications is most appropriate in the management of this patient?
Autonomic/CV Drugs US Medical PG Practice Questions and MCQs
Question 271: A 31-year-old woman comes to the physician because of intermittent episodes of stabbing right lower jaw pain for 6 weeks. The pain is severe, sharp, and lasts for a few seconds. These episodes commonly occur when she washes her face, brushes her teeth, or eats a meal. She does not have visual disturbances, weakness of her facial muscles, or hearing loss. Five weeks ago, she had an episode of acute bacterial sinusitis, which was treated with antibiotics. Which of the following is the most appropriate initial treatment for this patient's condition?
A. Doxepin
B. Microvascular decompression
C. Carbamazepine (Correct Answer)
D. Valacyclovir
E. Amoxicillin
Explanation: ***Carbamazepine***
- The patient's presentation with severe, sharp, short-lasting right lower jaw pain triggered by facial activities (washing, brushing, eating) is classic for **trigeminal neuralgia**.
- **Carbamazepine** is the first-line and most effective initial treatment for trigeminal neuralgia due to its mechanism of stabilizing neuronal membranes and reducing abnormal firing.
*Doxepin*
- **Doxepin** is a tricyclic antidepressant that can be used for neuropathic pain but is typically not the first-line agent, especially in severe, classic trigeminal neuralgia.
- Its primary use is often for chronic neuropathic pain or in conditions where mood disorders are comorbid, which is not indicated here as the primary concern.
*Microvascular decompression*
- **Microvascular decompression** is a surgical procedure considered for trigeminal neuralgia when medical management, particularly with carbamazepine, fails or is not tolerated.
- It is an invasive procedure and not an appropriate initial treatment for a newly diagnosed case before trying pharmacotherapy.
*Valacyclovir*
- **Valacyclovir** is an antiviral medication used to treat herpes virus infections, such as shingles (herpes zoster).
- While postherpetic neuralgia can cause facial pain, the described pain characteristics (brief, sharp, triggered) are more typical of trigeminal neuralgia, and there is no mention of a vesicular rash.
*Amoxicillin*
- **Amoxicillin** is an antibiotic used to treat bacterial infections.
- While the patient had a recent episode of sinusitis, her current pain is distinct from typical sinus pain and strongly suggestive of a neuropathic condition, not an ongoing bacterial infection.
Question 272: A 25-year-old woman presents to an urgent care center following a bee sting while at a picnic with her friends. She immediately developed a skin rash and swelling over her arm and face. She endorses diffuse itching over her torso. Past medical history is significant for a mild allergy to pet dander and ragweed. She occasionally takes oral contraceptive pills and diphenhydramine for her allergies. Family history is noncontributory. Her blood pressure is 119/81 mm Hg, heart rate is 101/min, respiratory rate is 21/min, and temperature is 37°C (98.6°F). On physical examination, the patient has severe edema over her face and severe stridor with inspiration at the base of both lungs. Of the following options, this patient is likely experiencing which of the following hypersensitivity reactions?
A. Type 2 - cytotoxic hypersensitivity reaction
B. Type 1 - anaphylactic hypersensitivity reaction (Correct Answer)
C. Both A & B
D. Type 4 - cell mediated (delayed) hypersensitivity reaction
E. Type 3 - immune complex mediated hypersensitivity reaction
Explanation: ***Type 1 - anaphylactic hypersensitivity reaction***
- The rapid onset of symptoms like **skin rash**, **swelling (angioedema)**, **diffuse itching (pruritus)**, and **stridor** immediately following a **bee sting** is characteristic of an immediate, IgE-mediated hypersensitivity reaction.
- This type of reaction involves the release of **histamine** and other mediators from **mast cells** and **basophils**, leading to systemic symptoms, including potential airway obstruction.
*Type 2 - cytotoxic hypersensitivity reaction*
- Type 2 hypersensitivity involves **antibodies** (IgG or IgM) binding to antigens on the surface of **target cells**, leading to cell destruction.
- Examples include **hemolytic anemia** or **transfusion reactions**, which do not match the presented symptoms of allergic rash and angioedema.
*Both A & B*
- This option is incorrect because the patient's symptoms are highly consistent with a **Type 1 reaction** and do not align with the mechanisms or clinical manifestations of a Type 2 reaction.
- The immediate and widespread allergic response points specifically to IgE-mediated anaphylaxis.
*Type 4 - cell mediated (delayed) hypersensitivity reaction*
- Type 4 hypersensitivity is a **delayed reaction** mediated by **T cells**, typically appearing 24-72 hours after exposure.
- Examples include **contact dermatitis** or the **tuberculin skin test**, which are much slower in onset and different in presentation than the immediate, severe reaction described.
*Type 3 - immune complex mediated hypersensitivity reaction*
- Type 3 hypersensitivity involves the formation of **immune complexes** (antigen-antibody complexes) that deposit in tissues, causing inflammation.
- Conditions like **serum sickness** or **lupus nephritis** are examples and typically have a slower onset and different clinical presentation (e.g., vasculitis, glomerulonephritis) compared to acute anaphylaxis.
Question 273: A 23-year-old man comes to the emergency department because of a 2-day history of painful swelling of the right hand. There is no associated recent trauma. Physical examination shows a 3 × 3-cm area of induration that is fluctuant and warm to the touch, consistent with an abscess. The patient consents to incision and drainage of the abscess in the emergency department. Following evaluation of the patient's allergy status, a short-acting, local anesthetic drug is administered via subcutaneous infiltration. Which of the following local anesthetics would provide the shortest duration of analgesia?
A. Etidocaine
B. Ropivacaine
C. Chloroprocaine (Correct Answer)
D. Mepivacaine
E. Lidocaine
Explanation: ***Chloroprocaine***
- **Chloroprocaine** is an **ester-type** local anesthetic, which are rapidly metabolized by plasma cholinesterases, resulting in a **short duration of action**.
- Its rapid metabolism makes it suitable for procedures requiring **brief analgesia** and a quick return to normal sensation.
*Etidocaine*
- **Etidocaine** is an **amide-type** local anesthetic known for its **long duration of action** due to its high lipid solubility and protein binding.
- It would provide analgesia for a significantly longer period than the brief procedure indicated.
*Ropivacaine*
- **Ropivacaine** is an **amide-type** local anesthetic with a **long duration of action**, commonly used for regional anesthesia and continuous infusions.
- It has a slower onset but prolonged effect, making it unsuitable for the shortest duration requirement.
*Mepivacaine*
- **Mepivacaine** is an **amide-type** local anesthetic with a **moderate duration of action**, longer than chloroprocaine but shorter than ropivacaine or bupivacaine.
- Its duration is not the shortest among the options provided, as ester-type anesthetics are generally shorter-acting.
*Lidocaine*
- **Lidocaine** is an **amide-type** local anesthetic with an **intermediate duration of action**, making it one of the most commonly used.
- While relatively short-acting compared to other amides, it is still longer than chloroprocaine due to its different metabolism.
Question 274: A 49-year-old woman is brought to the emergency department for a severe, sudden-onset generalized headache that began while she was riding an exercise bike at home that morning. After quickly getting off the bike and lying down, she lost consciousness. She was unconscious for a period of one minute. When she regained consciousness, she had neck stiffness, nausea, and two episodes of vomiting. She has hypertension. She does not smoke or drink alcohol. Her current medications include chlorthalidone and a multivitamin. She is in severe distress. Her temperature is 37.3°C (99.1F°), pulse is 88/min, respirations are 18/min, and blood pressure is 169/102 mm Hg. A CT scan of the head without contrast shows hyperdense material between the arachnoid mater and the pia mater. The patient is taken to the operating room for surgical clipping and transferred to the intensive care unit. Five days later, she has new-onset focal weakness of her left lower extremity. Her temperature is 37.1°C (98.8°F), pulse is 70/min, respirations are 17/min, and blood pressure is 148/90 mm Hg. Strength is 3/5 in the left lower extremity and 5/5 in the right lower extremity. Which of the following would most likely have been able to prevent this patient's condition?
A. Intravenous labetalol
B. Oral aspirin and clopidogrel
C. Intravenous sodium nitroprusside
D. Intravenous fresh frozen plasma
E. Oral nimodipine (Correct Answer)
Explanation: ***Oral nimodipine***
- This patient experienced **delayed cerebral ischemia** due to **vasospasm** following a **subarachnoid hemorrhage (SAH)**, indicated by her new-onset focal weakness five days after the initial event.
- **Nimodipine**, a calcium channel blocker, is the only medication proven to improve outcomes in SAH by preventing or reversing **cerebral vasospasm**.
*Intravenous labetalol*
- **Labetalol** is an antihypertensive used to control blood pressure, which might be elevated in SAH due to stress, but it does not prevent vasospasm.
- While blood pressure control is important, labetalol would not directly address the underlying mechanism of delayed cerebral ischemia.
*Oral aspirin and clopidogrel*
- **Aspirin** and **clopidogrel** are antiplatelet agents used to prevent arterial thrombotic events (e.g., stroke, myocardial infarction) and could worsen bleeding in the setting of SAH.
- They have no role in preventing or treating **cerebral vasospasm** after SAH.
*Intravenous sodium nitroprusside*
- **Sodium nitroprusside** is a potent vasodilator used for rapid blood pressure reduction in hypertensive emergencies, but it does not specifically target or prevent SAH-induced vasospasm.
- Its use might even cause a rapid drop in cerebral perfusion pressure, potentially worsening brain ischemia.
*Intravenous fresh frozen plasma*
- **Fresh frozen plasma (FFP)** is used to reverse coagulopathies or to replace clotting factors, which could be relevant if there was a coagulopathy contributing to bleeding or a need for rapid reversal of anticoagulation.
- However, FFP does not prevent **cerebral vasospasm** or delayed cerebral ischemia post-SAH.
Question 275: A 72-year-old woman comes to the emergency department because of severe pain in her right lower leg for 3 hours. She has also had worsening tingling that started 3 hours before. She has never had such pain in her leg in the past. Over the last couple months, she has occasionally had episodes of palpitations. She has hypertension and type 2 diabetes mellitus. Current medications include hydrochlorothiazide and lisinopril. Her pulse is 88/min and her blood pressure is 135/80 mm Hg. Physical examination shows a cool and pale right leg with delayed capillary filling. Muscle strength and tone in the right calf and foot are reduced. Femoral pulse is present bilaterally. Pedal pulses are absent on the right. Inhibition of which of the following would have most likely prevented this patient's condition?
A. Voltage-gated cardiac potassium channels
B. Synthesis of vitamin K-dependent factors (Correct Answer)
C. Receptors of sympathetic nervous system
D. Receptors for platelet aggregation
E. Voltage-gated cardiac sodium channels
Explanation: ***Synthesis of vitamin K-dependent factors***
- The patient's presentation with **sudden onset severe leg pain**, **cool and pale limb**, **absent pedal pulses**, and a history of **palpitations (suggesting atrial fibrillation)** points to acute limb ischemia due to an **embolus** likely originating from the heart.
- Atrial fibrillation leads to blood stasis and clot formation in the atria. Inhibiting the synthesis of **vitamin K-dependent coagulation factors (II, VII, IX, X, proteins C and S)** with an agent like warfarin would prevent these clots.
*Voltage-gated cardiac potassium channels*
- Inhibiting these channels (e.g., with **amiodarone** or **sotalol**) primarily affects cardiac repolarization and action potential duration, used to treat or prevent arrhythmias.
- While it may help manage the underlying atrial fibrillation, it does not directly prevent the formation of clots that have already developed or are forming, which is the immediate cause of the limb ischemia.
*Receptors of sympathetic nervous system*
- Blocking sympathetic receptors (e.g., **beta-blockers**) can help control heart rate and blood pressure, which might be used to manage atrial fibrillation or hypertension.
- However, this intervention does not directly target the coagulation cascade responsible for forming the embolus that occluded the leg vessel.
*Receptors for platelet aggregation*
- Inhibiting platelet aggregation (e.g., with **aspirin** or **clopidogrel**) would prevent arterial thrombosis, which is often seen in coronary artery disease or peripheral artery disease.
- The patient's sudden, severe symptoms and history of palpitations are more suggestive of an embolic event originating from the heart, where **anticoagulation (targeting fibrin formation)** is more effective than antiplatelet therapy alone.
*Voltage-gated cardiac sodium channels*
- Blocking these channels (e.g., with **flecainide** or **lidocaine**) is primarily used to treat or prevent certain cardiac arrhythmias by altering the depolarization phase of the action potential.
- Similar to potassium channel inhibition, this addresses the arrhythmia but does not directly prevent the formation of existing or impending thrombi responsible for the limb ischemia.
Question 276: A 27-year-old homeless man presents to the emergency department with abdominal pain and vomiting. He has a known history of intravenous drug use and has been admitted to the hospital several times before. On physical examination his temperature is 99°F (37.2°C), blood pressure is 130/85 mmHg, pulse is 90/min, respirations are 19/min, and pulse oximetry is 99% on room air. The patient is in obvious discomfort. There is increased salivation and lacrimation. Pupils are reactive to light and 5 mm bilaterally. Cardiopulmonary exam is unremarkable. There is diffuse abdominal tenderness to palpation with no rebound or guarding. Which of the following interventions would have prevented this patient’s current condition?
A. Naltrexone
B. Buprenorphine (Correct Answer)
C. Lorazepam
D. Naloxone
E. Bupropion
Explanation: ***Buprenorphine***
- This patient is presenting with symptoms consistent with **opioid withdrawal** (abdominal pain, vomiting, increased salivation, lacrimation). **Buprenorphine** is used for **opioid dependence treatment** as it's a **partial opioid agonist** that helps manage withdrawal symptoms and cravings, thus preventing acute withdrawal episodes.
- By stabilizing opioid receptors, buprenorphine, often combined with naloxone (Suboxone), reduces the risk of relapse and prevents the cycle of **intravenous drug use** that leads to withdrawal.
*Naltrexone*
- **Naltrexone** is an **opioid antagonist** used to prevent relapse in individuals who have achieved abstinence from opioids. It blocks the effects of opioids.
- However, administering naltrexone to someone actively using opioids or in withdrawal would precipitate or worsen withdrawal symptoms, making it unsuitable for preventing this acute presentation.
*Lorazepam*
- **Lorazepam** is a **benzodiazepine** primarily used to treat **anxiety**, **insomnia**, and **seizures**, and it is often used in **alcohol withdrawal**.
- While it can help manage some anxiety associated with opioid withdrawal, it does not address the underlying opioid dependence or prevent the physical symptoms of withdrawal itself, nor does it prevent the underlying cause of withdrawal which is abstinence from opioids.
*Naloxone*
- **Naloxone** is a potent, short-acting **opioid antagonist** used to **reverse opioid overdose** by rapidly displacing opioids from receptors.
- It would not prevent withdrawal; in fact, administering naloxone to an opioid-dependent individual would acutely precipitate severe withdrawal.
*Bupropion*
- **Bupropion** is an **antidepressant** that also aids in **smoking cessation**. It works by inhibiting the reuptake of norepinephrine and dopamine.
- It has no role in the prevention or treatment of opioid withdrawal and would not have altered this patient's current condition.
Question 277: A 45-year-old man with a history of recurrent gouty arthritis comes to the physician for a follow-up examination. Four weeks ago, he was diagnosed with hyperuricemia and treatment with allopurinol was begun. Since then, he has had another acute gout attack, which resolved after treatment with ibuprofen. His temperature is 37.1°C (98.8°F). Physical examination shows painless, chalky nodules on the metatarsophalangeal joint of his right foot. Laboratory studies show:
Serum
Creatinine 1.0 mg/dL
Uric acid 8.5 mg/dL
Cholesterol 278 mg/dL
Urine
Uric acid 245 mg/24 h (N = 240-755)
From a pharmacological mechanism perspective, based on the urine findings, this patient would theoretically benefit from treatment with which of the following drugs to prevent future gout attacks?
A. Indomethacin
B. Rasburicase
C. Colchicine
D. Prednisolone
E. Probenecid (Correct Answer)
Explanation: ***Probenecid***
- This patient's 24-hour urine uric acid excretion is **245 mg/24h**, which is at the lower end of the normal range (240-755 mg/24h). In gout management, patients excreting **<600 mg/24h** are typically classified as **underexcretors**, meaning their hyperuricemia is primarily due to decreased renal excretion of uric acid rather than overproduction.
- **Probenecid** is a **uricosuric agent** that works by inhibiting the URAT1 transporter in the proximal tubule, thereby blocking uric acid reabsorption and increasing renal excretion of uric acid.
- Since this patient is an underexcretor and allopurinol alone has not adequately controlled his serum uric acid (still 8.5 mg/dL with continued gout attacks), adding probenecid would directly address the underlying mechanism of **impaired renal excretion** and help lower serum uric acid levels.
*Indomethacin*
- **Indomethacin** is an **NSAID** used to treat acute gout attacks by inhibiting cyclooxygenase and reducing inflammation and pain.
- It does not lower serum uric acid levels and therefore does not prevent future gout attacks. It is used for symptomatic relief during acute flares, not for prophylaxis.
*Rasburicase*
- **Rasburicase** is a recombinant **urate oxidase** enzyme that converts uric acid to allantoin, a more water-soluble compound that is easily excreted.
- It is reserved for **acute severe hyperuricemia**, particularly in **tumor lysis syndrome**, and is administered intravenously. It is not used for chronic gout management or prophylaxis in ambulatory patients.
*Colchicine*
- **Colchicine** inhibits **microtubule polymerization**, thereby preventing neutrophil migration and activation in response to uric acid crystals.
- While it is effective for acute gout treatment and can be used for prophylaxis during initiation of urate-lowering therapy, it does not reduce serum uric acid levels. It only prevents the inflammatory response to existing crystals.
*Prednisolone*
- **Prednisolone** is a **corticosteroid** used to treat acute gout attacks by suppressing inflammation, particularly when NSAIDs are contraindicated (e.g., renal impairment, GI ulcers).
- Like other anti-inflammatory agents, it does not address the underlying hyperuricemia or lower uric acid levels, so it cannot prevent future attacks.
Question 278: A group of investigators is studying a drug to treat refractory angina pectoris. This drug works by selectively inhibiting the late influx of sodium ions into cardiac myocytes. At high doses, the drug also partially inhibits the degradation of fatty acids. Which of the following is the most likely effect of this drug?
A. Increased prolactin release
B. Decreased uric acid excretion
C. Decreased serum pH
D. Increased oxygen efficiency (Correct Answer)
E. Decreased insulin release
Explanation: ***Increased oxygen efficiency***
- Inhibiting the **late sodium current** reduces intracellular calcium overload, preventing diastolic dysfunction and improving myocardial relaxation.
- Partial inhibition of **fatty acid degradation** shifts myocardial metabolism towards glucose utilization, which is more oxygen-efficient.
*Increased prolactin release*
- This drug does not act on **dopamine receptors**, which are typically involved in regulating prolactin release.
- **Ranolazine**, the drug described, has no known effect on the endocrine system, specifically prolactin.
*Decreased uric acid excretion*
- **Uric acid excretion** is primarily affected by renal handling, often influenced by diuretics or drugs that compete for renal transporters, which is not a mechanism of this drug.
- This drug does not interfere with the **organic anion transporters (OATs)** responsible for uric acid secretion.
*Decreased serum pH*
- Changes in **serum pH** are usually associated with severe metabolic or respiratory disturbances, which are not direct effects of a drug targeting cardiac ion channels and metabolism.
- The drug's mechanism of action does not directly produce **acidic byproducts** or inhibit acid-base regulatory systems.
*Decreased insulin release*
- Insulin release is primarily stimulated by **glucose** and modulated by various endocrine pathways, none of which are directly targeted by a drug that inhibits cardiac sodium channels and fatty acid oxidation.
- There is no evidence that this class of drugs affects **pancreatic beta-cell function**.
Question 279: A 35-year-old woman comes to the physician because of recurring episodes of headache for the past 5 months. During this period, she has had headaches for approximately 20 days per month. The episodes last for about 2 hours each. She describes the headaches as dull, pressing, and non-pulsating holocranial pain. The symptoms do not increase with exertion. She has no vomiting, nausea, phonophobia, or photophobia. She has two children and has had a great deal of stress lately due to frequent fights with her husband. She appears well. Vital signs are within normal limits. Physical examination shows no abnormalities. Which of the following is the most appropriate pharmacotherapy for this patient?
A. Valproate therapy
B. Propranolol therapy
C. Amitriptyline therapy (Correct Answer)
D. Ergotamine therapy
E. Aspirin therapy
Explanation: ***Amitriptyline therapy***
- The patient's presentation with **dull, pressing, non-pulsating holocranial pain** that does not worsen with exertion, without nausea, vomiting, photophobia, or phonophobia, is highly suggestive of **tension-type headache (TTH)**.
- Given the high frequency (20 days/month) and duration (5 months), this is likely a **chronic tension-type headache**, for which **tricyclic antidepressants (TCAs)** like amitriptyline are the first-line prophylactic treatment.
*Valproate therapy*
- **Valproate** is primarily used for **migraine prophylaxis** and seizure disorders.
- The patient's headache characteristics (dull, pressing, non-pulsating, no photophobia/phonophobia) are not consistent with migraine.
*Propranolol therapy*
- **Propranolol** is a beta-blocker also used for **migraine prophylaxis**.
- As with valproate, the patient's headache features do not align with migraine, making propranolol less appropriate here.
*Ergotamine therapy*
- **Ergotamine** is an acute abortive medication for **migraine attacks**, not a prophylactic treatment for chronic headaches.
- Its use in frequent headaches carries a risk of **medication overuse headache**, and it is not suitable for tension-type headaches.
*Aspirin therapy*
- **Aspirin** is an **NSAID** used for acute pain relief in episodic headaches, including tension-type headaches.
- It is not considered an appropriate prophylactic therapy for **chronic, frequent tension-type headaches** and would not address the underlying issue effectively.
Question 280: A 47-year-old female presents to her primary care physician complaining of diarrhea and fatigue. She reports an eight-month history of increasingly frequent diarrhea, fatigue, and muscle weakness. She currently has over 15 episodes of watery diarrhea per day despite fasting. Her past medical history is notable for diabetes that is well controlled with metformin. Her temperature is 98.6°F (37°C), blood pressure is 100/70 mmHg, pulse is 95/min, and respirations are 18/min. Physical examination is notable for mild diffuse abdominal pain and facial flushing. An upper endoscopy is performed and the stomach is found to be less acidic than normal. In addition to correcting this patient’s dehydration, which of the following medications is most appropriate in the management of this patient?
A. Metoclopramide
B. Octreotide (Correct Answer)
C. Metronidazole
D. Omeprazole
E. Secretin
Explanation: ***Octreotide***
- This patient's symptoms (watery diarrhea, fatigue, muscle weakness, facial flushing, and achlorhydria) are highly suggestive of a **VIPoma** (vasoactive intestinal peptide-secreting tumor). **Octreotide** is a somatostatin analog that inhibits the release of VIP and is the most appropriate medication for symptomatic control.
- It also helps reduce **fluid and electrolyte losses** associated with severe secretory diarrhea caused by VIPomas.
*Metoclopramide*
- **Metoclopramide** is a prokinetic agent and antiemetic, primarily used for nausea, vomiting, and gastroparesis.
- It does not address the underlying pathology of a VIPoma or the severe secretory diarrhea seen in this patient.
*Metronidazole*
- **Metronidazole** is an antibiotic used to treat bacterial infections, particularly anaerobic infections and certain parasitic infections.
- There is no indication of an infectious cause for the severe diarrhea in this case, and it would not be effective for VIPoma-related symptoms.
*Omeprazole*
- **Omeprazole** is a proton pump inhibitor, used to reduce stomach acid production in conditions like GERD or peptic ulcers.
- While the patient has less acidic stomach, this is a symptom of a VIPoma (due to VIP's inhibitory effect on gastric acid secretion), not the primary issue, and omeprazole would further decrease acid, which is already low.
*Secretin*
- **Secretin** is a hormone involved in regulating gastric acid and pancreatic bicarbonate secretion, used diagnostically in some gastrointestinal disorders.
- It is not a therapeutic agent for chronic diarrhea or VIPoma.